Mr. Qin is a highly experienced executive in global business development, product licensing and partnership in life science industries. He has more than 15 years of business development experiences at leading biotech, specialty pharma and top medical institutes. Highly accomplished in striking corporate alliances and ventures, Mr. Qin has negotiated and closed over 20 commercial transactions with a large number of global health care organizations including Pfizer, Lilly, BMS, Myriad Genetics, Millennium, Mentor and Bausch Lomb, etc. Mr. Qin currently serves on the Advisory Board of CHI Scientific, Inc., a bioscience company in Maynar, MA. Mr. Qin has also served as Vice President of Biopharma Products at Nanobiosym Diagnostic, Inc (Medford, MA) responsible for commercial operation of its product lines targeting biopharma industries. Mr. Qin has also founded Genee Group LLC (Boston, MA). With operations in both US and China, Genee Group develops and markets proprietary IT solutions (LIMS) to lab researchers in life sciences. Prior to founding Biopharma Vision LLC, Mr. Qin was the Director of Business Development at Genzyme where he led overall business development functions. At Genzyme Biosurgery, he established and managed a cross-functional team responsible for new product licensing, acquisition and portfolio management. As the chief negotiator, he was instrumental in establishing global partnerships with biopharmaceutical and medical device companies.

Before he joined Genzyme, Mr. Qin was Sr. Director, Business Development at Control Delivery Systems,Inc., a specialty pharmaceutical company based in Watertown, MA. As the head of business development, Mr. Qin was fully responsible for new product planning and corporate alliances. He played critical roles in establishing and managing all CDS’s commercial alliances in ophthalmology, oncology and interventional cardiology.

Prior to his tenure at CDS, Mr. Qin was Director, Technology Transfer at MD Anderson Cancer Center, the largest cancer center in the U.S. There he managed technology licensing and venture start-ups for medical innovations developed at MD Anderson.

Mr. Qin received his Master’s in Business Administration from Rice University, MS in Molecular & Cellular Biology from the University of Massachusetts, Amherst and graduated from Wuhan University in China with BS in Molecular Biology & Virology.

» Chinese Bio

Dr. PC Zhu has extensive experience in biomedical research and commercial development in both US and China. In his years as a medical researcher at Harvard Medical School, he made a number of significant research discoveries, some of which have been featured in prestigious scientific journals including Nature, Nature Review, PNAS and Harvard Gazette. Several technological inventions from his bioresearch are currently being applied by leading US biopharmaceutical companies such as Alnylam and Invitrogen.

Dr. Zhu was a marketing researcher at NetEase.com, Inc. (NASDAQ: NTES) from 2000 to 2002. He has been a consultant for VitalBiotech (a Hong Kong based public company) in area of new business and commercial development. Dr. Zhu is also consulting for several Hi-tech Parks in China. Dr. Zhu has co-founded a Boston based Biotech company and served as VP of operations. He is also a founder and served the Boston Biotech Club (250 members) as Chairman for five years.

Dr. Zhu holds a PhD in Molecular Genetics from Fudan University, China; and MBA from University of Chicago Graduate School of Business.

Biopharma Vision is assembling a group of senior advisors with extensive expertise and leadership in global drug development and commercialization in order to serve broad needs of the client companies.

When appropriate, Biopharma Vision engages experts, key opinion leaders to assist in addressing certain business and medical issues related to the projects.